Medical Advertising Claims, Rankings, Awards and Discounts under NMC 2026

Why seemingly ordinary promotional language matters

Medical advertising reaches people making decisions about pain, disease, infertility, surgery and risk. The same superiority or urgency claims used to sell an everyday retail product may create an ethically significant distortion in a clinical setting. NMC clauses 8.1(i), (iii), (vi) and (ix) address unnecessary demand, superlatives, achievements, unrealistic treatment expectations and comparative claims. S1

'Best doctor', 'No. 1 hospital' and related language

The guidelines identify phrases such as 'best', 'top', 'most trusted' and number-one-style claims for scrutiny. Clause 8.1(ix) includes conditional reference to objective verification, transparent independently ascertainable methodology and other applicable law. But a methodology does not automatically defeat the separate ban on an RMP's self-promotional solicitation. S1

Before publishing an award, ask who paid for the ranking, whether the winner was independently selected, how the sample was drawn, whether the criteria were public, what location and year were evaluated and whether the statement attributes clinical superiority beyond what the data measures.

Clinical success claims need careful definitions

'100% safe', 'guaranteed pregnancy', 'painless procedure' or 'permanent cure' obscure case selection, contraindications, biological variability and known risks. Even a statistically measured success rate requires a defined denominator, timeframe, outcome measure, population and limitations; a scientifically accurate number may still be inappropriate in a promotional RMP advertisement.

Avoid replacing the unsupported statement with an equally misleading softer claim such as 'virtually risk-free'. Explain the relevant treatment decision and uncertainties instead.

Discounts and legitimate charge information

Clause 8.1(x) concerns discounts, limited-time offers, contests, coupons, gifts, cashbacks, referral benefits and free procedures used in a manner likely to encourage unnecessary consultation, investigation or treatment or solicitation. It expressly recognises that lawful disclosure of charges, packages and fees must be factual, transparent and non-misleading. S1

'Consultation charge ₹800' and 'Get surgery today at 50% off, last five slots' have different functions. The first can be a factual fee disclosure; the second applies commercial pressure to a clinical decision. The context, speaker and institutional rules still matter.

Fake reviews and engineered visibility

Clause 8.1(xii) addresses fake followers, likes, reviews, ratings, testimonials and manipulated search rankings, visibility or algorithms. A practitioner should not buy fabricated five-star reviews. Hospital directories should avoid implying that a paid preferred position is an independent measure of clinical quality. S1

Do not publicly identify reviewers as patients or disclose treatment details when responding to reviews. Reputation management must comply with confidentiality and truthfulness obligations.

Other statutory restrictions

Consumer law regulates misleading endorsements and representations; disease-specific product claims may engage the Drugs and Magic Remedies Act. An advertisement should not be cleared solely by an NMC word-search. S5 S10

Content-review checklist for claims

Document the precise claim, responsible speaker, citation or institutional proof, approved population or location, evidential limitations, visual implications, actual placement and why an exception or permitted category applies. If the claim implies guaranteed benefit or a comparison without sufficient support, remove it rather than disguising it with small-print qualifications.

Positive content alternatives

Show accurate facilities, treatment eligibility, clinical limitations, risk information, appointment logistics where permitted and trustworthy public-health education. Transparency about what is not guaranteed often improves the quality of the patient's decision.